HIFU demonstrates positive outcomes in management of prostate cancer, study shows

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

February 14, 2025

Vol.51 No.06

Clinical Roundup

Cortechs.ai, EDAP TMS announce OnQ prostate-assisted robotic HIFU procedure

Cortechs.ai and EDAP TMS SA announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco Prostate Center.

February 14, 2025

Vol.51 No.06

Clinical Roundup

UCLA-led study establishes link between early side effects from prostate cancer radiation and long-term side effects

Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Inherited WNT9B mutation linked to increased prostate cancer risk, study finds

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study published in JCO Precision Oncology.

February 07, 2025

Vol.51 No.05

Clinical Roundup

Wistar researchers identify target to overcome treatment-resistant melanoma

The lab of The Wistar Institute’s Jessie Villanueva has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. The team published their findings in the paper at the journal Science Translational Medicine.

February 07, 2025

Vol.51 No.05

Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

January 24, 2025

Vol.51 No.03

By NRG Staff